Supplementary MaterialsAdditional file 1: Figure S1. SUMO E3 ligases in myocardial IRI. Results In this study, we found dramatically decreased expression of PIAS1 after ischemia/reperfusion (I/R) in mouse myocardium and H9C2 cells. IWP-2 small molecule kinase inhibitor PIAS1 deficiency aggravated IWP-2 small molecule kinase inhibitor apoptosis and inflammation of cardiomyocytes via activating the NF-B pathway after I/R. Mechanistically, we identified PIAS1 as a specific E3 ligase for PPAR SUMOylation. Moreover, H9C2 cells treated with hypoxia/reoxygenation (H/R) displayed reduced PPAR SUMOylation as a result of down-regulated PIAS1, and act an anti-inflammatory and anti-apoptotic function through repressing NF-B activity. Finally, overexpression of PIAS1 in H9C2 cells could ameliorate We/R damage remarkably. Conclusions Collectively, our results demonstrate the key function of PIAS1-mediated PPAR SUMOylation in avoiding myocardial IRI. Electronic supplementary materials The IWP-2 small molecule kinase inhibitor online edition of this content (10.1186/s12860-018-0176-x) contains supplementary materials, which is open to certified users. strong course=”kwd-title” Keywords: Ischemia-reperfusion damage, PIAS1, SUMOylation, PPAR, NF-B Background Using the great rise in the typical of living, severe myocardial infarction (MI) has turned into a common cardiovascular crisis that causes a lot of fatalities in society. Well-timed and effective myocardial reperfusion is apparently the only healing strategy for reducing severe myocardial ischemic damage and restricting MI size [1]. Nevertheless, as the result of blood flow recovery towards the ischemic tissues, myocardial ischemia-reperfusion damage (IRI) can result in cell death and extra cardiac dysfunction. The root molecular systems of myocardial IRI involve irritation, calcium mineral overload, oxidative tension, cytokine infiltration and discharge of neutrophil [2]. Peroxisome proliferator-activated receptor (PPAR) is certainly a member from the nuclear receptor superfamily of ligand-inducible transcription elements, which provides been proven to play an essential function in a variety of pathological and physiological procedures, including blood sugar and lipid fat burning capacity, immunity and coronary disease [3]. Activation of PPAR can suppress the inflammatory response in cardiac tissues after ischemia/reperfusion (I/R) and therefore relieve ischemic pathological harm [4, 5]. Inside our prior study, we found that PPAR mediates the protective effect of quercetin against myocardial IRI via suppressing the NF-B pathway [6]. It has taken more than 20 years to identify protein modification by small ubiquitin-like modification (SUMOylation) [7]. Protein SUMOylation is usually a reversible process catalyzed by the activating (E1), conjugating (E2) and ligating (E3) enzymes and can be reversed by a family of SUMO-specific proteases (SENPs) [8, 9]. Only one E1 and one E2 enzyme have been reported in mammalian cells, whereas more than eight SUMO E3 ligases have been found to catalyze the transfer of SUMO from E2 UBC9 to a substrate. The protein inhibitor of activated STAT (PIAS) family of proteins [10], IWP-2 small molecule kinase inhibitor including PIAS1, PIAS3, PIASx, PIASx and PIASy, belong to the largest group of SUMO E3 ligases characterized by an SP-RING motif [11]. The requirement of the location of a RING-finger domain in the middle of a PIAS is essential to the E3 ligase activity of PIAS proteins. Various studies have shown that PIAS-mediated IWP-2 small molecule kinase inhibitor SUMOylation of target proteins is involved in a wide range of cellular processes [12C16]. We have previously shown that SENP1 deficiency exacerbates IRI in cardiomyocytes via an HIF1-dependent pathway [17], indicating the involvement of protein SUMOylation in myocardial IRI. However, it is unknown whether SUMO E3 ligases are regulated in myocardial IRI. In this study, we identify PIAS1 as a specific E3 ligase for PPAR SUMOylation in the myocardium. PIAS1-mediated PPAR SUMOylation protects against apoptotic and inflammatory injury by inhibiting NF-B activation after ischemia/reperfusion. NEU Our data suggest a potential clinical role of PIAS1 in IRI therapy. Results Expression of PIAS1 is usually reduced after ischemia/reperfusion in mouse myocardium and H9C2 cells To address the function and regulation of SUMO E3 ligases in myocardial IRI, we developed a mouse model of cardiac ischemia and reperfusion by surgical operation as described previously [17]. Along with the extended period of reperfusion (2-6?h), we found that mouse myocardium.
Supplementary MaterialsAdditional file 1: Figure S1. SUMO E3 ligases in myocardial
Categories
- 34
- 5- Receptors
- A2A Receptors
- ACE
- Acetylcholinesterase
- Adenosine Deaminase
- Adenylyl Cyclase
- Adrenergic ??2 Receptors
- Alpha2 Adrenergic Receptors
- Annexin
- Antibiotics
- ATPase
- AXOR12 Receptor
- Ca2+ Ionophore
- Cannabinoid
- Cannabinoid (GPR55) Receptors
- CB2 Receptors
- CCK Receptors
- Cell Metabolism
- Cell Signaling
- Cholecystokinin2 Receptors
- CK1
- Corticotropin-Releasing Factor1 Receptors
- DHCR
- DMTases
- DNA Ligases
- DNA Methyltransferases
- Dopamine D1 Receptors
- Dopamine D3 Receptors
- Dopamine D4 Receptors
- Endothelin Receptors
- EP1-4 Receptors
- Epigenetics
- Exocytosis & Endocytosis
- Fatty Acid Synthase
- Flt Receptors
- GABAB Receptors
- GIP Receptor
- Glutamate (Kainate) Receptors
- Glutamate (Metabotropic) Group III Receptors
- Glutamate (NMDA) Receptors
- Glutamate Carboxypeptidase II
- Glycogen Phosphorylase
- Glycosyltransferase
- GnRH Receptors
- Heat Shock Protein 90
- hERG Channels
- Hormone-sensitive Lipase
- IKK
- Imidazoline Receptors
- IMPase
- Inositol Phosphatases
- Kisspeptin Receptor
- LTA4 Hydrolase
- M1 Receptors
- Matrixins
- Melastatin Receptors
- mGlu Group III Receptors
- mGlu5 Receptors
- Monoamine Oxidase
- Motilin Receptor
- My Blog
- Neutrophil Elastase
- Nicotinic (??4??2) Receptors
- NKCC Cotransporter
- NMU Receptors
- Nociceptin Receptors
- Non-Selective
- Non-selective 5-HT
- OP3 Receptors
- Opioid, ??-
- Orexin2 Receptors
- Other
- Other Oxygenases/Oxidases
- Other Transcription Factors
- p38 MAPK
- p53
- p56lck
- PAF Receptors
- PDPK1
- PKC
- PLA
- PPAR
- PPAR??
- Proteasome
- PTH Receptors
- Ras
- RNA Polymerase
- Serotonin (5-HT2B) Receptors
- Serotonin Transporters
- Sigma2 Receptors
- Sodium Channels
- Steroid Hormone Receptors
- Tachykinin NK1 Receptors
- Tachykinin NK2 Receptors
- Tachykinin, Non-Selective
- Telomerase
- Thyrotropin-Releasing Hormone Receptors
- Topoisomerase
- trpp
- Uncategorized
- USP
Recent Posts
- 2012) using the Phenotypic Characteristic Search for human strains with markers for resistance to Adamantane, Oseltamivir, or both drugs
- Tissue were homogenized into single-cell suspensions and put through red bloodstream cell lysis
- A phase I/II study investigated the safety and efficacy of concurrent local palliative RT and durvalumab (PD-L1 inhibitor) in 10 patients with unresectable or metastatic advanced solid tumors [136]
- We believe that this hypothesis-generating study could open new avenues for exploring oxidative stress as a potential pathogenetic and, hypothetically, therapeutic target for mitigating CLL strong class=”kwd-title” Keywords: Leukemia, Lymphocytic, Gilbert’s, Syndrome Gilbert’s syndrome (GS) is the most common inherited disorder of bilirubin glucuronidation
- Such costs aren’t simple for tertiary-care hospitals in growing countries sometimes, since these already are powered by minimal budget which switches into provision of fundamental medical services mostly, laboratory, radiology, pharmacy services, and bed space
Tags
a 67 kDa type I transmembrane glycoprotein present on myeloid progenitors
and differentiation. The protein kinase family is one of the largest families of proteins in eukaryotes
Apoptosis
bladder
brain
breast
cell cycle progression
cervix
CSP-B
Cyproterone acetate
EGFR) is the prototype member of the type 1 receptor tyrosine kinases. EGFR overexpression in tumors indicates poor prognosis and is observed in tumors of the head and neck
EM9
endometrium
erythrocytes
F3
Goat polyclonal to IgG H+L)
Goat polyclonal to IgG H+L)Biotin)
GRK4
GSK1904529A
Igf1
Mapkap1
monocytes andgranulocytes. CD33 is absent on lymphocytes
Mouse monoclonal to CD33.CT65 reacts with CD33 andtigen
Palomid 529
platelets
PTK) or serine/threonine
Rabbit Polyclonal to ARNT.
Rabbit polyclonal to BMPR2
Rabbit Polyclonal to CCBP2.
Rabbit Polyclonal to EDG4
Rabbit polyclonal to EIF4E.
Rabbit polyclonal to IL11RA
Rabbit polyclonal to LRRIQ3
Rabbit Polyclonal to MCM3 phospho-Thr722)
Rabbit Polyclonal to RBM34
SB 216763
SKI-606
SNX-5422
STK) kinase catalytic domains. Epidermal Growth factor receptor
stomach
stomach and in squamous cell carcinoma.
TNFSF8
TSHR
VEGFA
vulva